Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia
Authors:
- 31 July 2009
- journal article
- review article
- Published by Wiley in Hematological Oncology
- Vol. 28 (1) , 3-12
Abstract
Chemotherapy regimens used for remission induction in AML have not changed significantly over the last several decades. However the recognition of the prognostic value of cytogenetics and genomics has been a major advance which is helping clarify the most optimal post‐remission consolidation strategy among various risk groups. We are not only beginning to realize the pitfalls of a ‘one‐fits‐all’ approach with intensive, cytarabine‐based chemotherapy as the mainstay, but we are finally beginning to reap the rewards of decades of basic, translational, and clinical research. Developing individualized, ‘targeted’ therapy for each AML patient based on unique molecular features of disease remains a daunting goal yet one that we can now begin to envision. Hypothesis‐based study designs—from pre‐clinical/laboratory experiments to phase‐I and subsequent efficacy trials—provide the foundation for advances in the diagnosis, risk stratification, and treatment for patients with AML. Here we critically review the literature for the management of AML, try to give recommendations regarding the appropriate induction and remission strategy, clarify the role of stem cell transplantation and discuss novel agents on the horizon. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 78 references indexed in Scilit:
- MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemiaBlood, 2008
- Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosminProceedings of the National Academy of Sciences, 2008
- Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B studyBlood, 2007
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood, 2006
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaBlood, 2006
- Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood, 2006
- Current therapeutic strategies for acute myeloid leukaemiaBritish Journal of Haematology, 2006
- Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazineMolecular Cancer Therapeutics, 2006
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003